MRI-guided radiation and Avastin for recurrent brain glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether using special MRI information to plan proton radiation, plus a drug called Avastin (bevacizumab), can help control recurrent glioblastoma (a fast-growing brain tumor) and improve outcomes. It mainly aims to treat tumor that has come back after prior standard radiation, using careful timing and imaging to target it safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have recurrent glioblastoma (or a close variant like gliosarcoma) confirmed by scans and/or pathology from a biopsy/re-surgery.
- Your tumor that has come back measures 6 cm or less across its largest linear length on T1 contrast MRI.
- You previously had standard brain radiation for a glioma (about 1.8–2 Gy per treatment, total up to 63 Gy).
- Your previous radiation must be finished at least 4–6 months ago (the exact timing depends on whether the new tumor is mostly outside or inside the prior high-dose area).
- You must be able to have MRI scans, provide written consent, and have acceptable blood counts and organ function (blood, liver, and kidney tests within set time windows).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.